TFX

Teleflex Incorporated [TFX] Stock Forecast

Q: What is Teleflex Incorporated stock symbol ?

Teleflex Incorporated is a US stock, located in Wayne of Pa and trading under the symbol TFX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TFX Stock Summary

Earnings have grown 6.57% per last year.

Earnings are expected to rise 29.8% next year

TFX has more than 3 years of cash runway (39 months)

Unstable dividend track record

EPS has been decreasing for the past 3 years (Yearly statements)

Top 10 Correlated ETFs

TFX

Top 10 Correlated Stocks

TFX

In the News

09:21 16 Apr 2024 TFX

Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC

Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.

10:20 16 Apr 2024 TFX

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.

09:40 16 Apr 2024 TFX

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls

Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.

10:36 16 Apr 2024 TFX

Compared to Estimates, Teleflex (TFX) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

08:46 16 Apr 2024 TFX

Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates

Teleflex (TFX) came out with quarterly earnings of $3.38 per share, beating the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.52 per share a year ago.

06:30 16 Apr 2024 TFX

Teleflex to Present at the 45th Annual Raymond James Institutional Investors Conference

WAYNE, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 5, 2024, at 1:40 p.m. (ET).

11:06 16 Apr 2024 TFX

Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

06:30 16 Apr 2024 TFX

Teleflex Announces Fourth Quarter 2023 Earnings Conference Call Information

WAYNE, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 22, 2024.

05:46 16 Apr 2024 TFX

3 Top Stock Picks from America's Leading SMID-Cap Fund

There are small-cap funds, and there are mid-cap funds, and those invest in both. These are what you call SMID-Cap funds.

09:01 16 Apr 2024 TFX

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.

TFX Financial details

Company Rating

Buy

Market Cap

10.09B

Income

356.33M

Revenue

2.97B

Book val./share

94.49

Cash/share

4.74

Dividend

1.36

Dividend %

0.55%

Employees

14.5K

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

28.84

Forward P/E

19.2

PEG

-139.51

P/S

3.94

P/B

2.7

P/C

44.56

P/FCF

30.67

Quick Ratio

2.23

Current Ratio

3.58

Debt / Equity

0.43

LT Debt / Equity

0.41

EPS (TTM)

7.58

EPS next Y

EPS next Q

EPS this Y

-2.07%

EPS next Y

45.05%

EPS next 5Y

158.18%

EPS last 5Y

-5.37%

Revenue last 5Y

2.76%

Revenue Q/Q

3.69%

EPS Q/Q

-77.4%

SMA20

-2.26%

SMA50

-12.2%

SMA100

2.37%

Inst Own

52.2%

Inst Trans

0.54%

ROA

ROE

10%

ROC

0.07%

Gross Margin

55%

Oper. Margin

16%

Profit Margin

14%

Payout

16%

Shs Outstand

Shs Float

Target Price

52W Range

177.63-276.43

52W High

-23.48%

52W Low

+19.32%

RSI

Rel Volume

0.49

Avg Volume

265.63K

Volume

130.61K

Perf Week

-2.63%

Perf Month

-5.41%

Perf Quarter

11.41%

Perf Half Y

10.48%

Beta

1.118

Volatility

4.56%, 5.06%

Prev Close

0.26%

Price

211.2

Change

-2.32%

TFX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	56.18	54.58	60.07	59.51	63.31
Net income per share	9.99	7.21	10.38	7.74	7.58
Operating cash flow per share	9.51	9.39	13.93	7.3	10.87
Free cash flow per share	7.29	7.44	12.4	5.61	8.92
Cash per share	6.98	8.52	9.98	7.26	4.74
Book value per share	64.49	71.77	80.27	85.76	94.53
Tangible book value per share	-30.79	-38.06	-22.2	-17.5	-20.75
Share holders equity per share	64.49	71.77	80.27	85.76	94.53
Interest debt per share	45.25	56.59	43.25	40.22	42.81
Market cap	17.39B	19.13B	15.36B	11.71B	11.71B
Enterprise value	19.1B	21.32B	16.89B	13.25B	13.42B
P/E ratio	37.69	57.06	31.65	32.24	32.87
Price to sales ratio	6.7	7.54	5.47	4.19	3.94
POCF ratio	39.57	43.84	23.59	34.22	22.94
PFCF ratio	51.63	55.34	26.5	44.52	27.94
P/B Ratio	5.84	5.73	4.09	2.91	2.64
PTB ratio	5.84	5.73	4.09	2.91	2.64
EV to sales	7.36	8.4	6.01	4.75	4.51
Enterprise value over EBITDA	28.98	30.9	21.18	17.78	16.41
EV to operating cash flow	43.46	48.86	25.92	38.72	26.28
EV to free cash flow	56.71	61.67	29.12	50.38	32.01
Earnings yield	0.03	0.02	0.03	0.03	0.03
Free cash flow yield	0.02	0.02	0.04	0.02	0.04
Debt to equity	0.67	0.77	0.52	0.46	0.43
Debt to assets	0.32	0.36	0.29	0.26	0.26
Net debt to EBITDA	2.59	3.17	1.91	2.07	2.08
Current ratio	2.32	2.63	2.1	2.43	2.32
Interest coverage	5.32	6.36	11.03	9.21	5.95
Income quality	0.95	1.3	1.34	0.94	1.43
Dividend Yield	0	0	0	0.01	0.01
Payout ratio	0.14	0.19	0.13	0.18	0.18
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.04	0.05	0.05	0.06	0.05
Intangibles to total assets	0.7	0.71	0.7	0.7	0.72
Capex to operating cash flow	-0.23	-0.21	-0.11	-0.23	-0.18
Capex to revenue	-0.04	-0.04	-0.03	-0.03	-0.03
Capex to depreciation	-0.48	-0.4	-0.3	-0.34	-0.38
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	120.39	107.93	136.9	122.23	127.01
ROIC	0.11	0.07	0.09	0.07	0.06
Return on tangible assets	0.24	0.16	0.23	0.17	0.17
Graham Net	-53.15	-61.68	-45.4	-42	-47.32
Working capital	743.28M	882.4M	749M	829.49M	800.66M
Tangible asset value	-1.42B	-1.77B	-1.04B	-820.93M	-975.03M
Net current asset value	-2.02B	-2.39B	-1.69B	-1.5B	-1.68B
Invested capital	0.67	0.77	0.52	0.46	0.43
Average receivables	392.48M	406.87M	389.32M	396.2M	426.15M
Average payables	104.81M	102.72M	110.38M	122.52M	129.53M
Average inventory	452.17M	494.88M	495.42M	528.08M	602.36M
Days sales outstanding	58.88	56.84	49.83	53.47	54.42
Days payables outstanding	34.03	30.87	34.25	36.74	36.36
Days of inventory on hand	157.59	154.52	138.37	167.59	172.17
Receivables turnover	6.2	6.42	7.32	6.83	6.71
Payables turnover	10.72	11.82	10.66	9.94	10.04
Inventory turnover	2.32	2.36	2.64	2.18	2.12
ROE	0.15	0.1	0.13	0.09	0.08
Capex per share	-2.22	-1.95	-1.53	-1.69	-1.95

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-04-02	2023-07-02	2023-10-01	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	16.16	15.14	15.82	15.88	16.47
Net income per share	1.68	1.63	2.37	2.92	0.66
Operating cash flow per share	2.09	1.79	1.83	4.29	2.95
Free cash flow per share	1.53	1.33	1.46	3.77	2.37
Cash per share	7.26	6.74	6.23	20.19	4.74
Book value per share	85.74	87.55	89.72	91.8	94.49
Tangible book value per share	-17.5	-15.06	-11.9	-8.4	-20.74
Share holders equity per share	85.74	87.55	89.72	91.8	94.49
Interest debt per share	39.46	37.72	35.93	46.23	41.53
Market cap	11.71B	11.82B	11.22B	9.21B	11.72B
Enterprise value	13.25B	13.31B	12.64B	10.47B	13.42B
P/E ratio	37.25	38.51	25.18	16.78	94.19
Price to sales ratio	15.45	16.63	15.09	12.33	15.14
POCF ratio	119.23	140.65	130.26	45.66	84.4
PFCF ratio	163.39	190	163.59	51.94	105.41
P/B Ratio	2.91	2.88	2.66	2.13	2.64
PTB ratio	2.91	2.88	2.66	2.13	2.64
EV to sales	17.48	18.73	17	14.03	17.34
Enterprise value over EBITDA	90.58	74.85	61.12	45.41	66.32
EV to operating cash flow	134.91	158.36	146.75	51.95	96.67
EV to free cash flow	184.88	213.92	184.29	59.1	120.73
Earnings yield	0.01	0.01	0.01	0.01	0
Free cash flow yield	0.01	0.01	0.01	0.02	0.01
Debt to equity	0.46	0.43	0.4	0.5	0.43
Debt to assets	0.26	0.25	0.24	0.29	0.26
Net debt to EBITDA	10.53	8.37	6.87	5.5	8.42
Current ratio	2.43	2.48	2.6	3.58	2.32
Interest coverage	4.55	6.27	8.08	5.94	3.2
Income quality	1.25	1.1	0.77	1.47	4.46
Dividend Yield	0	0	0	0	0
Payout ratio	0.2	0.21	0.14	0.12	0.51
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.06	0.06	0.05	0.05	0.05
Intangibles to total assets	0.7	0.7	0.69	0.63	0.72
Capex to operating cash flow	-0.27	-0.26	-0.2	-0.12	-0.2
Capex to revenue	-0.04	-0.03	-0.02	-0.03	-0.04
Capex to depreciation	-0.45	-0.36	-0.29	-0.42	-0.43
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	56.85	56.75	69.17	77.64	37.51
ROIC	0.01	0.02	0.02	0.02	0.01
Return on tangible assets	0.04	0.04	0.05	0.05	0.01
Graham Net	-41.99	-39.97	-37.25	-34.03	-47.3
Working capital	829.49M	852.34M	890.35M	1.51B	800.66M
Tangible asset value	-820.93M	-707.12M	-558.99M	-394.8M	-975.03M
Net current asset value	-1.5B	-1.38B	-1.23B	-1.08B	-1.68B
Invested capital	0.46	0.43	0.4	0.5	0.43
Average receivables	400.04M	409.43M	419.66M	427.25M	434.33M
Average payables	124.16M	131.52M	139.16M	136.38M	131.47M
Average inventory	554.3M	596.31M	622.83M	628.32M	625.65M
Days sales outstanding	48.54	51.91	51.98	51.27	51.57
Days payables outstanding	33.97	38.37	38.12	35.63	34.75
Days of inventory on hand	154.99	172.96	169.45	170.43	164.56
Receivables turnover	1.85	1.73	1.73	1.76	1.75
Payables turnover	2.65	2.35	2.36	2.53	2.59
Inventory turnover	0.58	0.52	0.53	0.53	0.55
ROE	0.02	0.02	0.03	0.03	0.01
Capex per share	-0.57	-0.47	-0.37	-0.52	-0.59

TFX Dividend History

TFX Frequently Asked Questions

What is Teleflex Incorporated stock symbol ?

Teleflex Incorporated is a US stock , located in Wayne of Pa and trading under the symbol TFX

What is Teleflex Incorporated stock quote today ?

Teleflex Incorporated stock price is $211.2 today.

Is Teleflex Incorporated stock public?

Yes, Teleflex Incorporated is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 265.63K
Market Capitalization 10.09B
Employee 14.5K
CEO Mr. Liam J. Kelly
Headquarters Wayne,PA,US
IPO Date 1980-03-17
Website https://www.teleflex.com

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.